HSP150 Antibody

What is HSP150 Antibody and what epitopes does it specifically recognize?

HSP150 Antibody is used to detect Heat Shock Protein 150 (also known as HSP12A in humans), which functions as a molecular chaperone involved in cellular stress responses. The antibody recognizes specific epitopes within the protein, typically within the Met695-Leu994 region in human HSP150/HSP12A (Accession # Q9Y4L1) . In fungal models, particularly Saccharomyces cerevisiae, HSP150 antibodies detect Pir family proteins that contain characteristic internal repeat sequences covalently attached to the cell wall . The antibody's specificity should be validated experimentally for each application as epitope accessibility may vary depending on protein conformation and experimental conditions.

How do HSP150 proteins differ between humans and yeast models?

While both are classified as heat shock proteins, human and yeast HSP150 proteins exhibit significant structural and functional differences:

The yeast HSP150 belongs to the Pir (Proteins with Internal Repeats) family and is covalently attached to the cell wall through β-1,3 glucan linkages . Interestingly, related Pir-like proteins have been identified in Candida albicans that cross-react with antibodies raised against S. cerevisiae HSP150, suggesting evolutionary conservation of certain epitopes across fungal species .

What are the optimized Western blot protocols for HSP150 Antibody?

For optimal Western blot analysis using HSP150 Antibody, the following methodological considerations are critical:

• Sample preparation: For human samples, lyse cells in RIPA buffer supplemented with protease inhibitors. For fungal samples, cell wall proteins require specialized extraction using either mild alkali treatment (30 mM NaOH) or β-1,3 glucanase digestion .

• Gel selection: Use 8-10% gels due to the high molecular weight (~150 kDa) of the target protein .

• Membrane transfer: PVDF membranes are recommended over nitrocellulose for higher protein retention, especially for high molecular weight proteins.

• Antibody concentration: Use Anti-Human ORP150/HSP12A at approximately 1 μg/mL for Western blot applications .

• Secondary antibody: HRP-conjugated secondary antibodies (such as Anti-Goat IgG) provide excellent signal when used at 1:2000-1:5000 dilution .

• Buffer conditions: For human HSP150/HSP12A, reducing conditions are recommended using Immunoblot Buffer Group 8 .

A representative protocol demonstrated successful detection of HSP150/HSP12A in HepG2 human hepatocellular carcinoma cell line and human breast cancer tissue samples, with specific bands visible at approximately 150 kDa .

How can I validate the specificity of HSP150 Antibody for my experimental system?

Validation of antibody specificity is crucial for reliable results. Implement these methodological approaches:

• Positive controls: Include lysates from cell lines known to express HSP150/HSP12A, such as HepG2 cells .

• Negative controls: Use cell lines where the target protein is absent or knockdown models (siRNA/CRISPR).

• Peptide competition assay: Pre-incubate the antibody with excess purified target peptide (Met695-Leu994 for human HSP150/HSP12A) ; signal disappearance confirms specificity.

• Cross-species reactivity testing: If working with multiple species, test antibody performance against each species' samples separately to establish cross-reactivity patterns.

• Molecular weight verification: Confirm band appearance at the expected molecular weight (~150 kDa) .

• Multiple antibody validation: When possible, compare results using antibodies from different sources or those targeting different epitopes of the same protein.

What are the recommended storage conditions for HSP150 Antibody to maintain its activity?

Proper storage is critical for maintaining antibody activity and reproducibility across experiments. Based on manufacturer recommendations, the following storage guidelines should be followed :

• Long-term storage: Store unopened antibody at -20°C to -70°C for up to 12 months from the date of receipt.

• After reconstitution:

  • For short-term use (≤1 month): Store at 2-8°C under sterile conditions

  • For long-term storage (≤6 months): Store at -20°C to -70°C under sterile conditions

• Critical handling notes:

  • Use a manual defrost freezer to prevent protein degradation

  • Avoid repeated freeze-thaw cycles by aliquoting the reconstituted antibody

  • Thaw aliquots at room temperature and use immediately

  • Verify antibody activity periodically if stored for extended periods

How should samples be prepared to optimize HSP150 detection in different experimental systems?

Sample preparation varies significantly between human and fungal systems:

For human samples:

• Use freshly prepared tissue or cultured cells when possible

• Lyse cells in buffer containing: 50 mM Tris (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and protease inhibitor cocktail

• Incubate lysates on ice for 30 minutes with periodic vortexing

• Centrifuge at 14,000×g for 15 minutes at 4°C and collect supernatant

• Determine protein concentration and load 20-40 μg per lane for Western blot analysis

For fungal samples:

• For cell wall-associated HSP150 extraction, use one of two methods:

  • Mild alkali treatment: 30 mM NaOH at 4°C for 16-18 hours

  • Enzymatic extraction: β-1,3 glucanase digestion at 37°C for 2-3 hours

• Neutralize alkali extracts and concentrate proteins by TCA precipitation

• For secreted HSP150, collect culture medium and concentrate using ammonium sulfate precipitation or ultrafiltration

What controls should be included when using HSP150 Antibody in immunological assays?

A robust experimental design requires appropriate controls to ensure valid interpretation of results:

• Positive control: Include lysates from HepG2 human hepatocellular carcinoma cells or breast cancer tissue for human HSP150/HSP12A detection .

• Negative control: Use cell lines with minimal expression of the target protein or include isotype control antibody matching the primary antibody species.

• Loading control: Probe for a housekeeping protein (β-actin, GAPDH) to verify equal protein loading across samples.

• Expression control: If studying stress-induced expression, include both stressed and non-stressed samples to demonstrate differential expression.

• Antibody specificity control: Include a peptide competition control where antibody is pre-incubated with excess target peptide before staining.

• Secondary antibody control: Omit primary antibody but include secondary antibody to identify non-specific binding.

How can HSP150 Antibody be used to investigate heat shock responses in different experimental systems?

HSP150 Antibody can be employed to study heat shock responses through several methodological approaches:

• Time-course experiments: Expose cells to heat shock (typically 37-42°C for mammalian cells, higher for thermotolerant organisms) for different durations and monitor HSP150 expression changes using Western blot or immunofluorescence.

• Transcriptional analysis: Correlate protein detection (via HSP150 Antibody) with mRNA expression through parallel RT-PCR or Northern blot analysis. In fungal systems, heat shock treatment (37°C for 45 minutes) has been shown to increase HSP150 mRNA levels compared to normal growth temperature (25°C) .

• Subcellular localization: Use HSP150 Antibody for immunofluorescence to track protein redistribution during stress responses.

• Growth media effects: Compare HSP150 expression in cells grown in different media compositions. Studies in C. albicans showed differential expression of HSP150-related transcripts when grown in defined medium with glucose versus galactose as carbon source .

• Cross-species comparison: Utilize the antibody's cross-reactivity properties to compare heat shock responses between related species, as demonstrated between S. cerevisiae and C. albicans .

Why might HSP150 Antibody show multiple bands or variable results in Western blot analysis?

Multiple bands or inconsistent results may occur for several technical and biological reasons:

• Protein isoforms: HSP150/HSP12A may exist in multiple isoforms due to alternative splicing, post-translational modifications, or proteolytic processing.

• Cross-reactivity: The antibody may detect related heat shock proteins, particularly when using polyclonal antibodies. In fungal systems, multiple bands were detected by anti-S. cerevisiae HSP150 antibody in C. albicans extracts, indicating cross-reactivity with homologous proteins .

• Protein degradation: Improper sample handling or insufficient protease inhibition can result in degradation products.

• Technical factors:

  • Insufficient blocking leading to non-specific binding

  • Suboptimal antibody concentration

  • Protein overloading causing band distortion

  • Incomplete protein transfer to membrane

• Species differences: When using the same antibody across different species, binding affinity and epitope recognition may vary significantly .

How can I distinguish between non-specific binding and true HSP150 signal?

To differentiate between specific and non-specific signals:

• Peptide competition assay: Pre-incubate the antibody with excess purified HSP150 peptide before application to the sample. True HSP150 signals should disappear or significantly diminish.

• Molecular weight verification: Confirm that the primary band appears at the expected molecular weight (~150 kDa for human HSP150/HSP12A) .

• Positive control comparison: Compare your sample bands with those from established positive control samples.

• Alternative detection methods: Confirm results using a different detection method (e.g., immunoprecipitation, ELISA, immunofluorescence).

• Multiple antibodies: When possible, verify with a second antibody targeting a different epitope of HSP150.

• Knockdown validation: If feasible, compare signals between wild-type and HSP150-depleted samples (siRNA, CRISPR).

How can rationally designed antibodies improve HSP150 detection in challenging experimental contexts?

Rational antibody design represents an advanced approach to overcome limitations in conventional antibody production:

• Epitope-specific targeting: Rational design allows development of antibodies targeting specific epitopes within disordered regions of proteins, which may be particularly useful for heat shock proteins that undergo conformational changes .

• Methodology: The process involves:

  • Identification of peptides complementary to target regions

  • Grafting these peptides onto the CDR (Complementarity-Determining Region) of an antibody scaffold

  • Structural validation through circular dichroism spectroscopy

  • Functional validation through ELISA and other binding assays

• Applications: While the search results don't specifically mention HSP150 antibody design, similar approaches have been successfully applied to other challenging protein targets, including proteins involved in neurodegenerative diseases .

• Advantages: Rationally designed antibodies can provide:

  • Higher specificity for particular epitopes

  • Better reproducibility across experiments

  • Reduced cross-reactivity with related proteins

  • Ability to target weakly immunogenic regions

What is the relationship between HSP150 and other heat shock proteins in disease pathogenesis?

Heat shock proteins, including HSP150, play complex roles in disease processes:

• Autoimmune responses: Antibodies against heat shock proteins have been detected in various diseases and may contribute to pathogenesis. Studies have shown elevated anti-HSP71 antibodies in patients with heat-induced illnesses, with titers correlating with disease severity .

• Biomarker potential: The presence and titer of antibodies against heat shock proteins could serve as biomarkers for stress responses and disease progression. For instance, workers experiencing abnormal environmental stress showed higher incidence of antibodies against HSP71 .

• Cross-interaction with therapeutic antibodies: Heat shock proteins like HSP70, HSP90, and trigger factor can predict antibody cross-interaction propensity, affecting therapeutic antibody clearance rates in experimental models .

• Diagnostic applications: Measurement of anti-HSP antibodies during disease progression and recovery could provide insights into patient responses to treatment. Studies have observed decreasing titers of anti-HSP71 antibodies during recovery from severe heat symptoms .

While the search results don't specifically address HSP150's role in disease pathogenesis, research on related heat shock proteins suggests potential implications worth investigating in future studies.

How does Western blot analysis of HSP150 compare with other detection methodologies?

Various techniques can be employed to detect HSP150, each with distinct advantages and limitations:

Western blot has been successfully used to detect HSP150/HSP12A in HepG2 cells and breast cancer tissue, showing specific bands at approximately 150 kDa . For measuring antibodies against heat shock proteins in clinical samples, ELISA-based methods have demonstrated utility in detecting anti-HSP antibodies in plasma from patients with heat-induced illnesses .

How can I optimize immunohistochemistry protocols for HSP150 detection in tissue samples?

While the search results don't provide specific information about immunohistochemistry (IHC) protocols for HSP150, the following methodological recommendations can be adapted from general practices for heat shock protein detection:

• Tissue fixation: Use 10% neutral buffered formalin for 24-48 hours; overfixation may mask epitopes.

• Antigen retrieval: Heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is often effective for heat shock proteins.

• Blocking: Thorough blocking with 5-10% normal serum matching the secondary antibody species plus 1% BSA reduces background.

• Primary antibody:

  • Optimize dilution (typically start with 1:50-1:200 for IHC)

  • Incubate overnight at 4°C for maximum sensitivity

  • Use positive control tissues known to express HSP150

• Signal amplification: Consider tyramide signal amplification for low-abundance targets.

• Counterstaining: Use hematoxylin for nuclear counterstaining but avoid overstaining.

• Validation controls:

  • No primary antibody control

  • Isotype control

  • Peptide competition control

  • Positive and negative tissue controls

How might HSP150 Antibody be utilized in studying cellular stress responses beyond heat shock?

HSP150 and other heat shock proteins respond to various cellular stresses beyond temperature changes:

• Oxidative stress: HSP150 Antibody could be used to monitor protein expression changes in response to reactive oxygen species (ROS) or oxidizing agents.

• Chemical exposure: Similar to studies that showed workers experiencing abnormal chemical stress had higher incidence of anti-HSP antibodies , HSP150 expression might serve as a biomarker for exposure to environmental toxins.

• Nutrient deprivation: Studies in C. albicans demonstrated that growth media composition affects HSP150-related transcript expression , suggesting potential applications in studying cellular adaptation to nutrient availability.

• Cross-kingdom interactions: The conservation of heat shock response mechanisms across species opens possibilities for studying host-pathogen interactions, particularly between humans and fungi that express HSP150 homologs.

• Therapeutic development: Understanding HSP150's role in stress responses could inform development of targeted therapies for conditions involving cellular stress dysregulation.

What are the methodological challenges in studying HSP150 antibodies in clinical samples?

Working with clinical samples presents unique challenges for HSP150 antibody research:

• Sample variability: Individual differences in baseline expression and antibody responses require larger sample sizes and careful statistical analysis.

• Detection sensitivity: The methodology used for anti-HSP antibody detection in clinical studies (immunoblotting on nitrocellulose membranes with diluted plasma samples) provides reliable but not highly sensitive detection .

• Standardization: Studies measuring anti-HSP antibodies in patient plasma have used different dilution series (1:10, 1:20, 1:40, and 1:80) , making direct comparison between studies challenging.

• Cross-reactivity: Antibodies against different heat shock proteins may cross-react, requiring careful validation to distinguish between responses to different HSPs.

• Clinical correlation: Establishing meaningful correlations between HSP150 antibody levels and disease outcomes requires longitudinal studies and comprehensive clinical data collection.

• Reference standards: Development of standardized positive controls and reference materials would improve inter-laboratory reproducibility for clinical studies involving HSP150 and anti-HSP antibodies.